REGADENOSON .08 mg/mL (Regadenoson INJECTION, SOLUTION) .08 mg/mL

Regadenoson .08 mg/mL is a pharmaceutical solution used for specific medical imaging procedures. This intravenous injection is designed to enhance diagnostic accuracy in certain cardiovascular assessments.

Strength

.08 mg/mL

Pack Size

5 mL in 1 SYRINGE, GLASS (16729-477-31)

Manufacturer / TM Owner

Accord Healthcare Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Regadenoson .08 mg/mL is primarily used in medical imaging to evaluate blood flow in the heart. It is often administered during stress tests to identify areas of reduced blood flow, which can help in diagnosing coronary artery disease. This medication is not typically used for general pain relief or other common ailments.

Side Effects

When administered, Regadenoson .08 mg/mL may cause temporary side effects such as headache, dizziness, or flushing. These effects are generally mild and short-lived. Some individuals may experience more pronounced reactions, but these are less common.

Precautions & Warnings

Regadenoson .08 mg/mL should be used with caution in individuals with certain heart conditions or a history of severe allergic reactions. It is important to inform healthcare providers about any existing medical conditions or medications being taken before administration.

Avoid Interactions

Regadenoson .08 mg/mL may interact with other medications, particularly those that affect heart rate or blood pressure. It is advisable to avoid alcohol and certain stimulants while using this medication. Always consult a healthcare provider for personalized advice.

Frequently Asked Questions

Regadenoson .08 mg/mL is used in medical imaging to evaluate blood flow in the heart, often during stress tests for diagnosing coronary artery disease.

Regadenoson .08 mg/mL is administered intravenously, typically in a clinical setting under the supervision of a healthcare provider.

Common side effects may include headache, dizziness, or flushing, which are usually mild and temporary.

No, Regadenoson .08 mg/mL is not intended for pain relief. It is specifically used for medical imaging procedures related to heart function.

Individuals with certain heart conditions or a history of severe allergic reactions should use Regadenoson .08 mg/mL with caution and under medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.